CSL just made its biggest bet in years. The company has secured worldwide rights to lixudebart, an anti-claudin-1 antibody from Alentis Therapeutics. The deal could reach $1.6 billion. CSL is under pressure. It recently posted its first operating loss in decades. Its rare disease pipeline has stalled after several setbacks.
CSL now gets immediate access to lixudebart. The drug is in phase 2 trials for ANCA-associated vasculitis with rapidly progressive glomerulonephritis (AAV-RPGN). This is a rare and aggressive autoimmune disease that can destroy kidney function fast. CSL will pay Alentis $355 million upfront. Another $1.2 billion could follow if milestones are met. Future profits will be split: 55% for CSL, 45% for Alentis. These details come from a Reuters financial review.
Lixudebart is positioned as a potentially first-in-class monoclonal antibody targeting claudin-1 for rare kidney and liver diseases, a novel approach highlighted by both Reuters and Bloomberg.
Targeting claudin-1 in severe disease
Lixudebart, once called ALE.F02, is built to bind exposed claudin-1. This tight junction protein helps keep cells together and controls cell signaling. In cancer, fibrosis, and chronic inflammation, claudin-1 can go haywire. That makes it a tempting drug target. Alentis leads this field. Lixudebart aims to block pro-inflammatory and pro-fibrotic signals right at the cell surface.
The phase 2 RENAL trial is testing lixudebart in patients with AAV-RPGN. This disease can quickly cause permanent kidney damage and lead to end-stage renal failure. CSL’s head of R&D, Dr Bill Mezzanotte, said, “Patients diagnosed with ANCA-associated vasculitis with rapidly progressive glomerulonephritis face rapid kidney function decline, leaving them at risk of irreversible damage even with currently available treatments.” He believes lixudebart could offer a new way to improve kidney function and stop the slide to end-stage disease. The drug may also help in focal segmental glomerulosclerosis (FSGS) and primary sclerosing cholangitis (PSC).
RTT News reports that CSL will fund the rest of the phase 2 RENAL trial, a planned phase 3 study in AAV-RPGN, and more studies in FSGS and PSC. This will push lixudebart further into rare kidney and liver disease research.
CSL's rare disease portfolio already includes Filspari for IgA nephropathy and FSGS, Zemaira/Respreeeza for alpha-1 antitrypsin deficiency, and the gene therapy Hemgenix for haemophilia B, reflecting the company's broader push into kidney medicine.
This deal lands as CSL faces a rough patch. The company has seen pipeline failures, supply problems for Hemgenix, and weak results from its $11.7 billion Vifor buyout. Leadership is shaky. CEO Paul McKenzie left suddenly in February. Interim managers are now running the show.
CSL is putting big money behind a first-in-class antibody. The company wants to get back on track in rare disease innovation. Targeting claudin-1 shows a shift. The industry is moving to attack the root causes of fibrosis and inflammation, not just the symptoms. The RENAL trial is underway. The biotech world is watching. Can lixudebart deliver for patients with severe kidney and liver disease? CSL is betting it can. For those following rare disease breakthroughs, this deal joins other recent pushes to solve tough biological problems, like the reported earlier effort to improve cell therapy storage.
